Trials / Conditions / Pulmonary Sarcoidosis

Pulmonary Sarcoidosis

27 registered clinical trials studyying Pulmonary Sarcoidosis — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis NCT06205121	Molecure S.A.	Phase 2
Enrolling By Invitation	An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis NCT06169397	Xentria, Inc.	Phase 2
Recruiting	Comparative Diagnostic Yield of Endobronchial Cryo Biopsy vs Forceps Biopsy in Patients With Suspected Sarcoid NCT06853834	Sanjay Gandhi Postgraduate Institute of Medical Sciences	N/A
Recruiting	A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis NCT05890729	Xentria, Inc.	Phase 1 / Phase 2
Unknown	Study Comparing Chronic Beryllium Disease to Pulmonary Sarcoidosis NCT06113991	Assistance Publique - Hôpitaux de Paris	—
Completed	Comparison of Different Exercise Training on Exercise Capacity and Fatigue in Patients With Sarcoidosis NCT05368883	Istanbul University - Cerrahpasa	N/A
Active Not Recruiting	Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis NCT05415137	aTyr Pharma, Inc.	Phase 3
Unknown	Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary Sarcoidos NCT05247554	Assistance Publique - Hôpitaux de Paris	Phase 3
Completed	Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis NCT04064242	Novartis Pharmaceuticals	Phase 2
Completed	The Effect of Inspiratory Muscle Training and Breathing Exercises Combined With Upper Extremity and Trunk in P NCT04173689	Istanbul University - Cerrahpasa	N/A
Completed	Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis NCT03824392	aTyr Pharma, Inc.	Phase 1 / Phase 2
Enrolling By Invitation	Biodistribution, Dosimetry and Performance of [68Ga]Ga-DOTA-Siglec-9 in Healthy and Patients With Rheumatoid A NCT03755245	Turku University Hospital	N/A
Completed	Breath Analysis in Patients With Suspected Sarcoidosis: The VOCs-IS Study NCT04318392	Manchester University NHS Foundation Trust	—
Completed	CASPA: CArdiac Sarcoidosis in PApworth NCT03599414	Papworth Hospital NHS Foundation Trust	—
Completed	Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis NCT02888080	Novartis Pharmaceuticals	Phase 2
Unknown	Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis NCT02824419	Turku University Hospital	Phase 2 / Phase 3
Unknown	Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS) NCT02188017	University of Cincinnati	Phase 4
Terminated	A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis NCT01732211	Pfizer	Phase 2
Completed	The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis NCT01587001	National Jewish Health	N/A
Unknown	Rehabilitation in Pulmonary Sarcoidosis: a Prospective Study NCT01384123	Meir Medical Center	—
Completed	Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis NCT01169038	Vanderbilt University	Phase 1
Completed	Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS). NCT02200146	University of Milano Bicocca	Phase 3
Completed	Antibody Response to Influenza Vaccine in Patients With Sarcoidosis NCT00828828	Shahid Beheshti University of Medical Sciences	—
Completed	Study of Nicotine Patches in Patients With Sarcoidosis NCT00701207	Elliott Crouser MD	EARLY_Phase 1
Terminated	Mycophenolate for Pulmonary Sarcoidosis NCT00262132	Medical University of South Carolina	Phase 3
Completed	Treatment of Pulmonary Sarcoidosis With Pentoxifylline NCT00001877	National Heart, Lung, and Blood Institute (NHLBI)	Phase 2
Recruiting	Role of Genetic Factors in the Development of Lung Disease NCT00001532	National Heart, Lung, and Blood Institute (NHLBI)	—